ERBB2 and breast carcinoma: In the same year, Abramczyk’s research team developed an innovative methodology for HER2 protein identification in breast cancer cells by combining RS, Raman Imaging, and AI models, offering significant advantages over currently employed diagnostic methodologies (Abramczyk et al., 2024).